Literature DB >> 16165125

[(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists.

Joel A Cassel1, Jeffrey D Daubert, Robert N DeHaven.   

Abstract

Alvimopan is a novel peripheral micro opioid antagonist in clinical development for the management of post-operative ileus and opioid-induced bowel dysfunction. We hypothesized that the long duration of action of alvimopan might be related to a slower dissociation rate from the micro opioid receptor compared to other shorter acting antagonists. The dissociation rate of alvimopan from the micro opioid receptor (t(1/2)=30--44 min) was comparable to that of the long acting partial agonist buprenorphine (t(1/2)=44 min), but was slower than those of the antagonists naloxone (t(1/2)=0.82 min) and N-methylnaltrexone (t(1/2)=0.46 min). Also, increases in the apparent affinities and potencies of buprenorphine and alvimopan, but not of naloxone and methylnaltrexone, were observed upon preincubation with the micro opioid receptor. Consistent with its long duration of action, alvimopan has a slow dissociation rate from the micro opioid receptor compared to other shorter acting antagonists and may be more potent if administered prior to dosing with exogenous opioids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16165125     DOI: 10.1016/j.ejphar.2005.08.008

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

Review 1.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 2.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

3.  Computational framework for predictive PBPK-PD-Tox simulations of opioids and antidotes.

Authors:  Carrie German; Minu Pilvankar; Andrzej Przekwas
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-08-08       Impact factor: 2.745

4.  Effects of Buprenorphine, Methylnaltrexone, and Their Combination on Gastrointestinal Transit in Healthy New Zealand White Rabbits.

Authors:  Manuel Martin-Flores; Bhupinder Singh; Courtney A Walsh; Elizabeth P Brooks; Lacic Taylor; Lisa M Mitchell
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

5.  The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.

Authors:  Pamela R Tsuruda; Ross G Vickery; Daniel D Long; Scott R Armstrong; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-04       Impact factor: 3.000

6.  Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.

Authors:  Philip Krieter; Shwe Gyaw; Roger Crystal; Phil Skolnick
Journal:  J Pharmacol Exp Ther       Date:  2019-04-02       Impact factor: 4.030

Review 7.  Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone.

Authors:  Richard L Rauck
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

8.  Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection.

Authors:  Michael Kraft; Robert Maclaren; Wei Du; Gay Owens
Journal:  P T       Date:  2010-01

9.  Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects.

Authors:  Philip Krieter; C Nora Chiang; Shwe Gyaw; Phil Skolnick; Rebekah Snyder
Journal:  Drug Metab Dispos       Date:  2019-04-16       Impact factor: 3.922

10.  Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.

Authors:  Ashraf Yassen; Erik Olofsen; Eveline van Dorp; Elise Sarton; Luc Teppema; Meindert Danhof; Albert Dahan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.